Search Results for: Standard di cura nel diabete 2024

Iss, ‘nel 2024 aderenza mammografia supera livelli pre-Covid’

La Piattaforma nazionale Liste di attesa, istituita con legge 107/2024 e disciplinata dal decreto del ministero della Salute del 17 febbraio 2025, nasce per centrare almeno due grandi obiettivi del…

L’Agenzia Italiana del Farmaco (Aifa) ha riconosciuto la rimborsabilità di un’ulteriore indicazione terapeutica per enzalutamide, sulla base dei risultati dello studio di Fase 3 EMBARK. Con questa autorizzazione enzalutamide diventa il primo ed unico inibitore del segnale del recettore degli androgeni che ha ottenuto la rimborsabilità per il trattamento di uomini adulti con cancro della prostata non metastatico ormono-sensibile (nmHSPC) con recidiva biochimica (BCR) ad alto rischio non idonei alla radioterapia di salvataggio

Un paziente con amiloidosi cardiaca da transtiretina (ATTR) oggi in Italia può ricevere diagnosi e cure molto diverse a seconda della Regione in cui vive. Eppure, questa malattia rara, spesso sottovalutata e diagnosticata troppo tardi, necessita di un percorso di cura rapido, personalizzato e multidisciplinare.
Per rispondere a questa sfida, Bistoncini Partners ha realizzato, con il contributo non condizionante di Pfizer, il Position Paper: “L’importanza dei PDTA personalizzati per la gestione del paziente con Amiloidosi da Transtiretina”, che viene oggi presentato nel corso di una conferenza stampa promossa dalla Senatrice Elena Murelli

New England Journal of Medicine, Volume 393, Issue 2, Page 198-200, July 10, 2025.

Introduction
Pain during supragingival scaling is often uncomfortable for patients, causing varying degrees of fear and anxiety, thus affecting patient comfort and compliance during treatment and reducing the effectiveness of treatment. Nitrous oxide/oxygen mixtures have the advantages of analgesic and sedative effects and are well tolerated. The purpose of this study is to explore the safety and effectiveness of a fixed inhaled nitrous oxide/oxygen mixture analgesia technology in the process of supragingival scaling and to provide empirical evidence for patients to reduce pain and reduce anxiety during supragingival scaling.

Methods and analysis
This is a randomised, double-blind, placebo-controlled trial that is expected to enrol 120 patients. We will recruit patients undergoing supragingival scaling procedures. Participants will be allocated randomly to either the intervention group (A) or the control group (B) in a 1:1 ratio. Dental hygienists, dental assistants, patients and the collector of the data will all blind themselves to the study. Nurses who carry out the intervention will give doctors envelopes containing the patient’s identification code and the group to which they have been assigned (Group A or Group B). Group A will be given the standard treatment plus a premixed combination of nitrous oxide and oxygen, while Group B will receive oxygen alone in the standard treatment without any sedative analgesics, all under uniform conditions. Evaluations will take place prior to treatment (T0), at 5 min into the intervention (T1), at 15 min during the intervention (T2) and 5 min following the treatment (T3). The primary outcomes will be pain scores and anxiety scores, which will be assessed using the Numeric Rating Scale and the Visual Analogue Scale for Anxiety. Secondary outcome indicators in this study will include patients’ vital signs, side effects and physician and patient satisfaction.

Ethics and dissemination
This study was approved by the Medical Ethics Committee of the 960th Logistics Support Force of the People’s Liberation Army. Written informed consent form will be obtained from each participant. Results will be submitted for publication in peer-reviewed journals.

Trial registration number
ChiCTR2400090261.

Protocol version
Protocol version 1.1.

Introduction
Septic shock-associated acute kidney injury (AKI) is known to carry a poor prognosis. The present study aims to evaluate the effect of absorptive blood purification on haemodynamic status and clinical outcomes in patients with septic shock-associated AKI.

Methods and analysis
This multicentre, randomised controlled trial will evaluate an adsorbent filter (oXiris) in patients with abdominal septic shock requiring continuous renal replacement therapy (CRRT). The study plans to recruit 192 participants from intensive care units, who will be randomly assigned to either the intervention group (oXiris set) or the control group (ST 150 set). The primary endpoint is the reduction in norepinephrine equivalence following the initiation of CRRT. Key secondary endpoints include changes in cardiac index and systemic vascular resistance index, as measured by pulse indicator continuous cardiac output, following CRRT initiation, as well as overall survival and kidney recovery rates.

Ethics and dissemination
The study will be conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. The Ethics Committee of Shanghai Jiaotong University School of Medicine, Renji Hospital (no. LY-2024–082-B) approved this study on 27 May 2024. The results will be published in peer-reviewed journals and presented at international conferences.

Trial registration number
NCT06504316 (https://clinicaltrials.gov/study/NCT06504316).

Introduction
Despite an increasing amount of research related to gender-affirming treatment (GAT) outcomes among transgender and gender-diverse (TGD) people (ie, people who experience discomfort or distress in the misalignment between their gender and sex assigned at birth) in recent years, the evidence base for current recommendations is suboptimal. One contributing factor is the heterogeneity in the outcomes and outcome measures used. This study seeks to address this challenge by developing a foundational core outcome set (COS) to be used for TGD adults receiving GAT in Sweden.

Methods
Recommendations from the Core Outcome Measures in Effectiveness Trials initiative will be used to address this aim in four phases. Phase 1, an umbrella review of peer-reviewed literature and international guidelines in GAT will be conducted to identify relevant outcomes. In phase 2, we will solicit input from TGD individuals through the review of patient and interest organisations’ reports and an anonymous survey to identify outcomes of personal significance. In phase 3, using the Delphi method, 2–3 rounds of assessment will be conducted where researchers, healthcare professionals, policy-makers and TGD adults rate the identified outcomes by perceived importance. In phase 4, a consensus meeting will convene representatives from all stakeholder groups to finalise the COS.

Analysis
The results of this study will consist of a COS for GAT regarding TGD adults in Sweden. Participant survey responses will be evaluated using interpretive analysis to identify core outcomes. During each of the Delphi rounds, Likert-type scale ratings will be aggregated for outcomes to advance or be eliminated in each round.

Ethics and dissemination
The study has received ethical approval by the Swedish Ethical Review Authority (Umeå medicine department, Registration number: 2024-04672-01). The results of this study will be published open-access and disseminated through TGD interest organisations and a Swedish research network for gender dysphoria.

Trial registration number
COMET registration number 3223.

Introduction
Distal radius fractures account for one-fifth of all fractures in the active elderly population and may cause chronic pain, loss of hand function and reduced work productivity, imposing a significant socioeconomic burden. Most are initially treated with closed reduction and casting, but 30% subsequently require surgery due to insufficient realignment. The current approaches for analgesia for closed reduction are suboptimal. A brachial plexus nerve block provides complete pain relief and muscle relaxation distal to the elbow, potentially creating better conditions for realignment of the fractured bone ends. This may ultimately translate into reduced need for surgery and result in better functional outcomes and fewer complications compared to a haematoma block, which is the current standard care in Denmark.

Methods and analysis
The BLOCK Trial is an investigator-initiated, parallel-group, allocation-concealed, outcome assessor and analyst-blinded, superiority, randomised, controlled, clinical multicentre trial performed at 11 Danish emergency departments. Eligible adult patients with a distal radius fracture who need closed reduction will be included and allocated 1:1 to either an ultrasound-guided brachial plexus nerve block or a haematoma block. The primary outcome is the proportion of patients with distal radius fracture surgery 90 days after closed reduction. We will include 1716 participants to detect or discard a relative risk reduction of surgery of 20%. Secondary outcomes include treatment-related complications, patient-reported wrist function, pain during closed reduction and proportion of patients with unacceptable radiographic fracture position immediately after closed reduction.

Ethics and disseminationf
The trial is approved by the Danish Medicines Agency and the Danish Research Ethics Committees (EU CT number: 2024-512191-35-00). All results will be summarised on www.theblocktrial.com, clinicaltrials.gov and euclinicaltrials.eu after publication. Primary and secondary outcome results from 0 to 90 days will be presented in the main article and submitted to a peer-reviewed journal. Results from outcomes on the 12-month follow-up will be presented separately.

Trial registration number
NCT06678438.

Negli adolescenti con diabete di tipo 1, l’aggiunta all’insulina dell’SGLT2 inibitore dapagliflozin a basso dosaggio ha migliorato la funzionalità renale e il controllo glicemico, secondo quanto rilevato dallo studio clinico ATTEMPT presentato al congresso 2025 dell’American Diabetes Association (ADA).

Uno studio pubblicato su BMC Gastroenterology ha evidenziato che nei pazienti con epatite C cronica (CHC), genotipo 3a, età, cirrosi, ipertensione e insulino-resistenza e altri fattori indipendenti sono associati allo sviluppo di diabete di tipo 2 (T2DM). Interventi precoci nei pazienti a rischio possono migliorare la prognosi e ridurre le complicanze gravi.

Negli ultimi anni, il concetto di remissione ha acquisito un valore strategico nella cura delle spondiloartriti e di altre malattie reumatologiche, Di questo tema ha parlato la prof.ssa Maria Antonietta d’Agostino (Direttore UOC Reumatologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma) nel corso del congresso EULAR e, in questa sede, proponiamo alcuni highlight emersi nel corso della sua relazione.

In Italia, il carcinoma della prostata rappresenta la neoplasia più diffusa tra gli uomini over 50, incidendo per circa il 30% su tutti i tumori maschili, con 40.192 nuovi casi stimati solo nel 2024. È stata presentata oggi, in Senato la campagna di sensibilizzazione ‘Allo Specchio della Salute – uno spazio di confronto sul carcinoma prostatico’, pensata per coinvolgere l’intera comunità nel dibattito intorno alla gestione e cura di questa patologia. Un’intera giornata dedicata al carcinoma della prostata suddivisa in due appuntamenti sinergici e xomplementari: la conferenza stampa seguita dalla campagna di awareness.